Phase II Dose-ranging Study of APD421 in PONV
- Registration Number
- NCT01510704
- Lead Sponsor
- Acacia Pharma Ltd
- Brief Summary
To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 215
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Low dose APD421 APD421 1mg dose level Mid Dose APD421 APD421 5mg dose level High Dose APD421 APD421 20mg dose level
- Primary Outcome Measures
Name Time Method Post-operative Nausea or Vomiting 24 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (12)
University Hospital
🇫🇷Nancy, France
Klinikum Ludwigshafen
🇩🇪Ludwigshafen, Germany
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Hôpital mère enfant
🇫🇷Bron, France
Hôpital Huriez
🇫🇷Lille, France
Hôpital FOCH
🇫🇷Paris, France
Hautepierre Hospital
🇫🇷Strasbourg, France
Universität Heidelberg
🇩🇪Heidelberg, Germany
Charité - Universitätsmedizin
🇩🇪Berlin, Germany
University Hospitals of Würzburg
🇩🇪Würzburg, Germany
HELIOS Klinikum Aue
🇩🇪Aue, Germany
Philipps University
🇩🇪Marburg, Germany